This is a single arm, Phase IIA clinical trial assessing the safety and efficacy of
atezolizumab in combination with paclitaxel, trastuzumab, and pertuzumab in 50 patients with
locally advanced, unresectable, or metastatic HER2-overexpressing breast cancer. Due to
concerns that corticosteroids may have a negative effect on tumor immunity expected with
addition of atezolizumab to the standard of care regimen, patients will receive premedication
with dexamethasone only for weeks 1 and 2 of the weekly paclitaxel, and then corticosteroid
premedication will be discontinued subsequently.
Patients must have pathologically confirmed HER2-overexpressing breast cancer that is locally
recurrent, unresectable, or metastatic, with measurable disease as defined by RECIST v1.1.
Tumor measurements and bone scans will be performed every 9 weeks while patients are on
HER2 Positive Breast Cancer,
her2/neu-positive breast cancer,
her2-positive breast cancer
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.